Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Chardan Capital Downgrades Vascular Biogenics to Neutral

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.
byBenzinga Newsdesk
July 21, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Chardan Capital analyst Matthew Barcus downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts